LENZ Therapeutics Reports Fourth Quarter, Full-Year Financial Results as Sales of Presbyopia Drop Gain Momentum

Published on March 25, 2026
SAN DIEGO—LENZ Therapeutics, Inc. (Nasdaq: LENZ), a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, yesterday reported financial results for the fourth quarter and full year ended December 31, 2025 and provided a corporate update. Approved by the FDA in July 2025, VIZZ is a once-daily aceclidine-based eye drop for the treatment of age-related presbyopia. Launched in the U.S. in October 2025, VIZZ was broadly available by mid-November and generated product revenue of approximately $1.6 million in the fourth quarter, driven by over 20,000 filled prescriptions.
Continue reading on website
Other news

Altair Eyewear, Inc. and Cole Haan Renew Global Licensing Agreement for Cole Haan Eyewear

March 25, 2026
NEW YORK—Altair Eyewear, Inc., a division of Marchon Eyewear and a subsidiary of VSP Vision, and Cole Haan, the American lifestyle and accessories brand, have announced a multi-year renewal of their global eyewear licensing agreement for the exclusive worldwide design, development, production and distribution of optical and sunglass collections under the Cole Haan brand name. Marchon and Cole Haan

AOA presses for FDA enforcement focused on ‘Eyebot’ Kiosk

March 25, 2026
Detailed legal complaint documents patient safety, health and product claim concerns—and seeks immediate federal agency enforcement action.